BioSpace News Archive

Charles River Laboratories International, Inc. (NYSE: CRL) and Rznomics Inc. today announced a viral vector contract development and manufacturing organization (CDMO) partnership.

NiKang Therapeutics Inc. today announced that Dr. Anne Borgman has been appointed to the company’s Board of Directors.

This week, the Association of Clinical Research Organizations (ACRO)’s RBQM Working Group published a paper in DIA’s Therapeutic Innovation & Regulatory Science journal titled, Risk-Based Monitoring in Clinical Trials: 2021 Update.

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has applied with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat Rett Syndrome, a rare genetic neurological disorder.

NTT Research, Inc., a division of NTT (TYO:9432), today announced plans to hold Upgrade 2023, the NTT Research Summit, as an in-person event on March 15-16, 2023.

Eisai announced today the presentation of research across various types of gastrointestinal cancers during the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI23), which is taking place in-person in San Francisco, California and virtually from January 19-21.

SQI Diagnostics Inc. announced that its Rapid Acute Lung Injury Diagnostic IL-6 Severity Triage Test has been installed in two University Health Network hospitals in Toronto to use as a clinical aid to help assess respiratory patients in the Emergency Department and as part of a study to help fight the growing respiratory health crisis in EDs.

The American College of Clinical Pharmacology® (ACCP) published a Position Paper entitled “The Importance of Diversity and Inclusion in Drug Development and Clinical Trial Conduct” addressing the topic of diversity in clinical trials and drug development.

Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EXG102-031.

Cryoport, Inc. today announced a new strategic partnership with Syneos Health® (NASDAQ: SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success.